The therapeutic community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s demonstrating significant promise in clinical trials for treating obesity. Unlike some current weight loss treatments, retatrutide appears to offer a significant substantial decrease in body size and enhance metabolic marker… Read More